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Abstract: Sonidegib and vismodegib are hedgehog pathway inhibitors (HhIs) approved for the treatment
of advanced basal cell carcinoma (BCC). Until recently, vismodegib was the only targeted treatment
available for patients with locally advanced BCC (laBCC) in cases where surgery and radiotherapy are
inappropriate. Sonidegib has recently been approved and now presents an alternative treatment option.
The clinical differences between the two HhIs in patients with laBCC are unclear, as no head-to-head
randomized controlled trials are or will be initiated. Moreover, there were important differences in the
designs of their pivotal studies, BOLT (sonidegib) and ERIVANCE (vismodegib), and these differences
complicate evidence-based analysis of their relative efficacy and safety profiles. In this paper, a group
of clinical experts in the management of laBCC summarizes the clinical and pharmacological profiles of
sonidegib and vismodegib based on published data and their own clinical experience. One key difference
between the two pivotal studies was the criteria used to assess BCC severity. ERIVANCE (a single-arm
phase II trial) used the conventional Response Evaluation Criteria in Solid Tumors (RECIST), while the
more recent double-blind randomized BOLT trial used the stringent modified RECIST (mRECIST). A
pre-planned analysis adjusted the outcomes from BOLT with RECIST-like criteria and this enabled the
experts to discuss relative efficacy outcomes for the two treatments. Centrally reviewed objective response
rate (ORR) for vismodegib was 47.6% (95% CI 35.5-60.6) at 21-month follow-up using RECIST. After
adjusting with RECIST-like criteria, the ORR for sonidegib according to central review at 18-month
follow-up was 60.6% (95% CI 47.8-72.4). Both treatments were associated with similar patterns of
adverse events. Sonidegib and vismodegib share the same efficacy and tolerability profiles, but their
pharmacokinetic profiles show several differences, such as volume of distribution and half-life. Further
studies are needed to understand how these differences may impact clinical practice.
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Abstract 
Sonidegib and vismodegib are hedgehog pathway inhibitors (HhIs) approved for the treatment of 
advanced basal cell carcinoma (BCC). Until recently, vismodegib was the only targeted treatment 
available for patients with locally advanced BCC (laBCC) in cases where surgery and radiotherapy are 
inappropriate. Sonidegib has recently been approved and now presents an alternative treatment option. 
The clinical differences between the two HhIs in patients with laBCC are unclear, as no head-to-head 
randomized controlled trials are or will be initiated. Moreover, there were important differences in the 
designs of their pivotal studies, BOLT (sonidegib) and ERIVANCE (vismodegib), and these differences 
complicate evidence-based analysis of their relative efficacy and safety profiles. In this paper, a group 
of clinical experts in the management of laBCC summarizes the clinical and pharmacological profiles of 
sonidegib and vismodegib based on published data and their own clinical experience. One key 
difference between the two pivotal studies was the criteria used to assess BCC severity. ERIVANCE (a 
single-arm phase II trial) used the conventional Response Evaluation Criteria in Solid Tumors 
(RECIST), while the more recent double-blind randomized BOLT trial used the stringent modified 
RECIST (mRECIST). A pre-planned analysis adjusted the outcomes from BOLT with RECIST-like 
criteria and this enabled the experts to discuss relative efficacy outcomes for the two treatments. 
Centrally reviewed objective response rate (ORR) for vismodegib was 47.6% (95% CI 35.5–60.6) at 21-
month follow-up using RECIST. After adjusting with RECIST-like criteria, the ORR for sonidegib 
according to central review at 18-month follow-up was 60.6% (95% CI 47.8–72.4). Both treatments 
were associated with similar patterns of adverse events. Sonidegib and vismodegib share the same 
efficacy and tolerability profiles, but their pharmacokinetic profiles show several differences, such as 
volume of distribution and half-life.  Further studies are needed to understand how these differences 
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Basal cell carcinoma (BCC) is the most common form of cancer in the Caucasian population.1 Most 
BCCs can be removed by surgery, but occasionally they progress deep into the tissue or metastasize 
to the extent where curative surgery and radiotherapy are not feasible.1–4 In a systematic analysis at 
one tertiary referral center, locally advanced BCC (laBCC) comprised <1% of all BCCs in almost 10,000 
patients4.  In some patients with laBCC, surgical intervention can result in disfiguring deformity, loss of 
function and morbidity 3–7, and Nägeli and Dummer have proposed criteria to help define when surgery 
and irradiation is inappropriate (Table 1).8 
Multidisciplinary care is essential in the management of laBCC, and effective communication is vital to 
ensure patients have realistic expectations from their treatment. Alongside effective adverse effect (AE) 
management, pre-treatment education about potential AEs increases the likelihood that patients will 
tolerate optimal treatment durations.  
Aberrant signaling of the hedgehog pathway is important to the pathophysiology of BCC1,7 and two 
licensed hedgehog pathway inhibitors (HhIs), sonidegib and vismodegib, are indicated for the treatment 
of laBCC in cases where surgery and radiotherapy are inappropriate.  
Vismodegib was EMA-approved for treatment of laBCC and symptomatic metastatic BCC based on 
outcomes from the ERIVANCE study.9,10 Sonidegib, which is comparatively new to the market, gained 
EMA-approval for laBCC treatment based on the results of the BOLT study.11,12 Although these two 
agents act on the same pathway and have similar indications, there are currently no evidence-based 
recommendations to help clinicians choose between them, as there are no randomized, controlled trials 
comparing sonidegib with vismodegib and the pivotal phase II studies, BOLT and ERIVANCE, did not 
compare the HhIs with standard of care.9,11 Thus, the clinical differences between sonidegib and 
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comparison between sonidegib and vismodegib by using statistical methods to reduce potential 
confounders between the two pivotal studies.13 However, while this study adjusted for some key 
differences in patient baseline characteristics, it did not consider numerous other important differences 
between BOLT and ERIVANCE.13 
Without head-to-head comparisons, an expert discussion using the published data on sonidegib and 
vismodegib is valuable in understanding their relative study outcomes, without introducing additional 
statistical analyses or further confounders. The expert panel of this review paper is made up of 
clinicians who are internationally recognized experts in the treatment of laBCC, and are involved in 
developing national and/or international non-melanoma guidelines, together with a pharmacologist. All 
the experts are from countries where both HhIs have been approved for the treatment of laBCC. 
Sonidegib and vismodegib have different pharmacokinetic profiles 
Studies into the pharmacokinetic profiles of sonidegib and vismodegib have shown several differences. 
Sonidegib and vismodegib demonstrate a high level of binding (>99%) to the plasma proteins alpha-1-
acid glycoprotein (AAG) and human serum albumin (HSA).10,12,14 However, the plasma protein binding 
of sonidegib within a dose range of 200–800 mg was non-concentration-dependent, whereas 
vismodegib at 150 mg or higher demonstrated concentration-dependent binding.15–17 Overall, 
vismodegib plasma levels strongly correlated with AAG plasma levels, due to saturable, highly 
reversible drug-protein binding. Once saturated, vismodegib showed further low-affinity binding to the 
high-capacity binder HSA.15,16,18 Therefore, vismodegib 150 mg delivered the maximum serum 
concentration and a higher dosage will not increase the unbound drug level in the plasma (Fig. 1).17 In 
contrast, increasing sonidegib dosage resulted in increasing level of unbound, active drug in the plasma 
until dose-limited absorption occured.19  
Vismodegib has a volume of distribution of 16–27 liters, suggesting that it is largely confined to the 
plasma and has limited tissue penetration.10,20 In contrast, sonidegib seems to be more lipophilic than 
vismodegib and has a volume of distribution of >9,000 liters, indicating extensive distribution in the 
tissues.12,19,21 Consequently, the concentration of sonidegib is six-times higher in skin than in plasma.12 
In theory, these evidences suggest that sonidegib is more extensively distributed in the skin compared 
with vismodegib, which may explain potential differences in efficacy and toxicity between them. 
Sonidegib has a long elimination half-life of 28–30 days and achieves steady state after 3–4 
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days.10,18–20,22 In general, the more extended the half-life, the longer it takes to reach steady state and 
maximum effect, and AEs will take longer to subside on stopping treatment. 
However, further studies are needed to compare the impact of dosage titration (both up and down-
titration) between sonidegib and vismodegib. 
BOLT and ERIVANCE are appropriate for comparative discussion  
The BOLT study was a multicenter, international, randomized, double-blind, pivotal, phase IIb clinical 
trial assessing the efficacy and safety of sonidegib, with a primary endpoint of overall response rate 
(ORR) determined by MRI and multiple biopsies via central review.11 Although BOLT participants were 
randomized 1:2 to sonidegib 200 mg or 800 mg, the expert panel discussion focused on outcomes of 
sonidegib 200 mg in patients with laBCC because this is the approved dose and indication.11,12  
ERIVANCE was a non-randomized, single-arm multicenter, international, pivotal, phase IIb clinical trial 
assessing the efficacy and safety of vismodegib 150 mg in patients with laBCC and metastatic BCC, 
with ORR by central review as the primary endpoint.9 
Vismodegib was also assessed in two other phase II studies, STEVIE AND MIKIE.23,24 However, 
because of important differences (summarized in Table 2), the expert group considered that data from 
these studies were not appropriate for head-to-head comparison of efficacy and their review therefore 
focused on the pivotal studies, ERIVANCE and BOLT. 
ERIVANCE and BOLT had similar baseline patient characteristics, and both used ORR by central 
review as the primary endpoint (Table S1, supporting information).9,11 However, beyond this, there are 
many important differences between these studies (Table 2).9,11 
BOLT endpoints assessment criteria were more stringent compared with ERIVANCE 
i.  Complete, partial and overall response rates 
There are important differences between BOLT and ERIVANCE regarding lesion assessment and this 
has complicated evidence-based analysis of the relative efficacy and safety of sonidegib and 
vismodegib. Since some BCCs demonstrate slow growth, it can be difficult to differentiate stable 
disease (SD) from progressive disease (PD), particularly over short assessment periods. In addition, 
regressed lesions present scar-like plaques, which can be difficult to differentiate complete response 
(CR) from partial response (PR). In order to reduce the risk of this bias, this review focuses on ORR, 










This article is protected by copyright. All rights reserved 
ii. Investigator review vs central review 
BOLT and ERIVANCE both assessed response by central and investigator review (Fig. 2).9,11 In 
general, investigator review showed more positive outcomes than central review.9,11,15,25,26 In the 
primary analysis of ERIVANCE, the concordance between assessment by central review and 
investigator review was 60%; ORR by central review was 42.9% (95% CI 30.5–56.0), with 20.6% CR 
and 22.2% PR, whereas ORR by investigator review was 60.3% (95% CI 47.2–71.7), with 31.7% CR 
and 28.6% PR.9 Similar trends were observed in BOLT and in subsequent follow-ups in both studies 
(Table S2, S3, supporting Information).9,11,15,25,26 Central review is more rigorous and was the primary 
endpoint of both pivotal studies, and is thus more appropriate for comparison. 
iii. RECIST vs mRECIST  
ERIVANCE used the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 protocol, 
while BOLT used modified RECIST (mRECIST) criteria (Table 3).9,11,27,28 There is no evidence to 
support mRECIST being more reproducible than RECIST, but mRECIST is considered to have more 
stringent evaluation criteria and is more likely to detect minimal signs of disease and disease 
progression (Table 4).25 Therefore, mRECIST may classify a given treatment response as partial, 
whereas the same response may be considered as complete using RECIST. Similarly, mRECIST is 
more likely to detect signs of slight disease progression that may be classified as SD under RECIST. 
The use of these different evaluation criteria adds a further complication to comparing outcomes 
between the trials. However, BOLT included a pre-planned analysis which adjusted study outcomes 
with RECIST-like criteria, similar to those used in ERIVANCE.15 
iv. Follow-up period 
The follow-up periods were different between the two studies and there were no reported outcomes 
with the same minimum follow-up period (Fig. 2).9,11,15,25,26,29 The closest follow-up time points across 
the studies were the 18-month analysis for BOLT and the 12-month update (21-month follow-up) for 
ERIVANCE.9,11,15,25,26,29 
As a result of all these inter-study variations, the expert panel considered the most representative data 
for discussion were the ORRs based on RECIST criteria by central review at 18–21-month follow-up. 
The outcomes from the final analyses were not considered appropriate for discussion, as ERIVANCE 
did not include a central review at the 30-month update. 
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In BOLT, 66 patients with laBCC were treated with sonidegib 200 mg, and in ERIVANCE, 63 patients 
with laBCC were treated with vismodegib 150 mg.9,11 The baseline demographics and patient 
characteristics between the two studies were similar, with key differences being the greater number of 
patients with prior surgery and prior radiotherapy in ERIVANCE (Table S1, supporting information).9,11   
At the initial 9-month follow-up of ERIVANCE, the primary endpoint (ORR by central review using 
RECIST) for vismodegib 150 mg was 42.9% (95% CI 30.5–56.0), with 20.6% CR and 22.2% PR (Table 
S3, supporting information).9   At the 21-month follow-up, ORR increased to 47.6% (95% CI 35.5–60.6), 
with 22.2% CR and 25.4% PR (Table 5).26 The final outcomes of ERIVANCE at 39-months were 
reported by investigator review only.29 
Based on the US Food and Drug Agency recommendation, the BOLT study of sonidegib used 
mRECIST criteria determined by central review and reported an ORR of 47.0% (95% CI 34.6–59.7) at 
primary 6-month follow-up, with 3.0% CR and 43.9% PR, increasing to 56.1% (95% CI 43.3–68.3) at 
18-month follow-up, with 4.5% CR and 51.5% PR (Table S2, supporting information).11,15 At long-term 
follow up (30 months) sonidegib was associated with an ORR of 56.1% (95% CI 43.3–68.3); 4.5% CR 
and 51.5% PR.15  
After adjusting the response in BOLT using RECIST-like criteria, ORR by central review for sonidegib at 
18 months increased by a small proportion from 56.1% (CR, 4.5%; PR, 51.5%) to 60.6% (CR, 22.7%; 
PR, 37.9%) (Table 6).15 In contrast, CR increased 5-fold using the less stringent RECIST-like criteria.15 
Similar trends were observed in the primary analysis and 30-month follow-up (Table S3, S4, supporting 
information). This increase in CR was primarily due to lesions previously considered as PR under 
mRECIST being considered CR under RECIST-like criteria (Fig. 3). The adjusted CR rate was similar to 
that observed in ERIVANCE at 21-months.15,26 
The centrally reviewed median duration of response (mDOR) and median progression-free survival 
(mPFS) with sonidegib in BOLT were higher than those observed with vismodegib in ERIVANCE.15,26 
Ideally, data from the final analyses of the two pivotal studies should be used to review mDOR and 
mPFS. However, the study outcomes for vismodegib at the final analysis were only reported by 
investigator review, so 21-month follow-up data were used for discussion instead. The centrally 
reviewed mDOR was 26.1 months (95% CI NE) with sonidegib at 30-month follow-up and 9.5 months 
(95% CI 7.4–21.4) with vismodegib at 21-month follow-up (Table 7, Fig. 4).10,15,26 In the investigator 
review, the mDOR was 15.7 months (95% CI 12.9–20.2) with sonidegib at 30-month follow-up and 26.2 
months (95% CI 9.0–37.6) with vismodegib at 39-month follow-up (Table S2,S3, supporting 
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month follow-up and 9.5 months (95% CI 7.4–14.8) with vismodegib at 21-month follow-up (Table 7, 
Fig. 5).15,26  In the investigator review, the mPFS was 19.4 months (95% CI 16.6–23.6) with sonidegib 
at 30-month follow-up and 12.9 months (95% CI 10.2–28.0) with vismodegib at 39-month follow-up 
(Table S2,S3, supporting information).15,29 The estimated overall survival (OS) was 93.2% at 30-month 
follow-up with sonidegib (Table S2, supporting information) and the estimated OS was 85.5% at 39-
month follow-up with vismodegib (Table S3, supporting information).15,29  
These outcomes in laBCC patients were based on different lengths of treatment exposure, as well as 
two separate studies, which added complexity to drawing a conclusion. Analyses of quality of life (QoL) 
results are not reported here but they are included in the discussion. 
Sonidegib and vismodegib share a similar tolerability profile  
At the final 39-month data cut-off in ERIVANCE, patients’ median duration of exposure to vismodegib 
was 12.9 months and 96 of 104 patients with laBCC or mBCC treated with vismodegib 150 mg 
discontinued their treatment.29 About 57% of patients had discontinued vismodegib 150 mg due to AEs 
or physicians’/patients’ decision by 39 months.29 All patients experienced ≥1 treatment emergent AEs 
(TEAEs).29 Similar rates of discontinuation were observed in BOLT, where patients’ median duration of 
exposure to sonidegib was 11.0 months at the final 30-month analysis and 73 of 79 patients with laBCC 
or mBCC treated with sonidegib 200 mg discontinued their treatment.15 About 53% of patients had 
discontinued sonidegib 200 mg due to AEs or physicians’/patients’ decision by 30 months.15  In both 
studies, AEs were the primary reason for patients’ and physicians’ decisions to discontinue 
treatment.15,29 
Over half of the patients with laBCC or mBCC treated with vismodegib 150 mg in ERIVANCE at 39-
months experienced AEs including muscle spasms (71.2%), alopecia (66.3%), dysgeusia (55.8%) and 
weight loss (50.0%) (Table S5, supporting information).29 Most AEs were mild. The most frequent grade 
≥3 AE was weight loss (8.7%), follow by muscle spasms (5.8%) and fatigue (4.8%) (Table S5, 
supporting information).29 The shortest median time to onset of AEs with vismodegib 150 mg was 
dysgeusia at 1.48 months (95% CI 0.99–2.07), followed by muscle spasm at 1.89 months (95% CI 
1.35–2.73) (Fig. 6).26 Median time to onset of weight loss was the longest, at 6.13 months (95% CI 4.5–
7.36).26 
At 30-months, the most commonly reported TEAEs (any grade) in patients with laBCC or mBCC treated 
with sonidegib 200 mg (n=79) were muscle spasms (54.4%), alopecia (49.4%) and dysgeusia (44.3%) 
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elevated CK (6.3%), weight loss (5.1%) and muscle spasms (2.5%) (Table S5, supporting 
information).15 The shortest median time to onset of AEs with sonidegib 200 mg was fatigue at 1.08 
months (95% CI 0.53–3.6), followed by muscle spasm at 2.07 months (95% CI 1.87–3.19) (Fig. 6).30 
The longest median times to onset of AEs were diarrhea (95% CI 1.35–10.32) and weight loss (95% CI 
4.70–8.31) at 6.47 months.30  
Initial assessment of published data from both pivotal studies showed that sonidegib had an 
approximately 10% lower incidences of most AEs compared with vismodegib at final analyses.15,29  
Overall, TEAEs reported with sonidegib were slightly less frequent and less severe compared with 
vismodegib.15,29  The time to onset of AEs also indicated that patients treated with sonidegib may 
experience AEs slightly later than with vismodegib, with the exception of fatigue (Fig 6).15,26,29,30 
However, as these data cannot be directly compared, the above can only serve as indicative values. In 
general, sonidegib and vismodegib are associated with similar patterns of AEs, suggesting HhI class-
dependent effects.15,26,29,30  
Further studies are needed to provide a conclusive outcome 
The key clinical questions regarding sonidegib and vismodegib focus around their relative risk–benefits 
and whether switching between the two HhIs could be useful. 
One of the most important differences between these agents is their pharmacokinetic profile. Sonidegib 
at 200 mg and 800 mg demonstrated non-concentration-dependent plasma protein binding, whereas 
vismodegib at 150 mg or higher demonstrated concentration-dependent plasma protein binding.15–17 
Sonidegib has a longer half-life (28–30 days) and higher volume of distribution (>9000 liters) than 
vismodegib (4–12 days and 16–27 liters, respectively).10,12,19–21 How these differences may impact the 
use of these HhIs in clinical practice remains an open question. For example, the differences in time to 
steady state and plasma concentration between the two HhIs do not seem to correlate with the effect of 
the drugs – the median time to response was 3.9 months for sonidegib in BOLT and 5.6 months for 
vismodegib in ERIVANCE.9,11 However, sonidegib demonstrated a longer time to AE onset (except for 
fatigue), with even less frequent and less severe AEs compared with vismodegib.26,29,30 Nevertheless, it 
was suggested that switching between the two HhIs is unlikely to be useful from a safety perspective, 
as the two drugs showed the same mode of action and similar patterns of AEs.   
Key methodological differences between BOLT and ERIVANCE meant that only specific datasets were 
selected for discussion, and data from the pre-planned analysis from BOLT was used to aid 
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RECIST.25 Nevertheless, the centrally reviewed ORR in BOLT at 18-months was comparable using 
either set of lesion assessment criteria, while the rate of CR increased with RECIST-like criteria.15 This 
adjusted CR rate was similar to those observed in ERIVANCE at 21-months.15,26 The centrally reviewed 
mDOR and mPFS with sonidegib at 30-months were longer than vismodegib at 21-months.15,26 In the 
investigator review, vismodegib demonstrated a longer mDOR, but shorter mPFS at 39-months 
compared with sonidegib at 30-months.10,15,26 However, these data are only indicative of the 
comparative efficacy profiles of the two HhIs, as they were based on different treatment exposure 
lengths from two separate studies. 
Patients with laBCC treated with sonidegib demonstrated sustained or improved QoL in BOLT, despite 
development of AEs.11,25,31 Patients with laBCC treated with vismodegib showed no positive changes 
from baseline on either the physical or emotional portions of the Short Form-36 questionnaire in 
ERIVANCE.31,32 However, these data cannot be compared, as different health-related QoL scales were 
used and the assessment frequency also differed.  A review of the QoL outcomes from the STEVIE 
study showed that vismodegib was associated with clinically meaningful improvement in the emotional 
domain using the Skindex-16 scale.33 However, differences in isolated health-related QoL scale 
dimensions may result in bias and should not be compared. 
In the absence of a head-to-head comparison study, the clinical relevance of pharmacokinetic profile of 
sonidegib needs further studies to provide conclusive evidence. Intermittent trials, sequential trials or 
cross-over trials of the two HhIs, in laBCC patients who discontinued treatment due to AEs, may 
demonstrate the impact of the pharmacokinetic profiles. Further exploratory studies of real-world 
populations may shed light on how pharmacokinetic profile differences may affect the use of sonidegib 
and vismodegib in clinical practice.  
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Table 1 Criteria to define when surgery and irradiation is inappropriate in laBCC.8 
 >5 BCCs, if patient suffers from genetic syndromes  
 BCC >10 mm, relapsing after 2 surgeries in critical locations (e.g. periocular and 
perioral areas) 
 BCC infiltrating in bone/cartilage/other structures and curative resection unlikely 
 Relapsing BCC after multiple surgeries and/or radiotherapy 
 Advanced BCC in patients who do not qualify for general anesthesia 
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Table 2 Overview of sonidegib and vismodegib clinical trials in patients with locally advanced basal cell 
carcinoma.  
 BOLT11 ERIVANCE9 STEVIE23 MIKIE24 
Treatment  Randomized 1:2 to 
sonidegib 200 mg 
QD (laBCC, n=66) 
or 800 mg QD 
(laBCC, n=128) 
Vismodegib 150 
mg QD (laBCC, 
n=63) 
Vismodegib 150 
mg QD (laBCC, 
n=1,119) 
Randomized 1:1 to 
vismodegib 150 mg QD 
in an intermittent 
schedule of 12 weeks 
vismodegib followed by 
8 weeks placebo 
(n=116) or 24 weeks 
induction followed by an 
intermittent schedule of 
8 weeks placebo 
followed by 8 weeks 
vismodegib (n=113) 
Inclusion criteria ≥18 years old 
Inoperable laBCC 






marrow, liver, and 
renal function 







≥18 years old 
Inoperable laBCC 








≥18 years old 
Multiple BCC, including 
participants with Gorlin 
syndrome, with at least 6 
clinically evident BCC 
lesions (3 of which 




Adequate renal and 
hepatic function and 
hematopoietic capacity 
Exclusion criteria Major surgery 
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Participation in an 
investigational 
study in the 







that may cause 
muscle damage 
Concurrent medical 
conditions that may 
interfere or 
potentially affect 
the interpretation of 
the study 
Oral drugs or lack 
of physical integrity 
of the upper 
gastrointestinal 





Participation in an 
investigational 
study in the 
previous 4 weeks  




which may be 
considered 







use of the 
investigational drug 
and an inability to 
swallow capsules 
Concurrent 
antitumor therapy  
 
Completion of the 
most recent anti-
tumor therapy less 
than 21 days prior 









Pregnancy or lactation 
Participation in an 
investigational study in 
the previous 4 weeks  
Known or suspected 
alcohol abuse 
One of the following 
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BCC assessment 
criteria 
mRECIST RECIST RECIST – 
Primary endpoint ORR (CR+PR) by 
central review 
ORR (CR+PR) by 
central review 
Safety Mean percent change 
from baseline in the 
number of clinically 



























Mean percent change 
from baseline in total 
size of three target BCC 
lesions 
Percentage of patients 
with at least 50% 
reduction in the number 
of BCC 
Percentage of patients 
with new BCC lesions 
Percent change in total 
number of BCC relative 
to baseline at Week 85, 
97 and 125 
CR, complete response; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; 
laBCC, locally advanced basal cell carcinoma; mRECIST; modified RECIST; NE, not estimable; ORR, 
objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; QD, 
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Table 3 Evaluation of Target Lesions by RECIST V1.0 and mRECIST. 
 mRECIST*28 RECIST V1.027 
CR Histology: negative ≥2 biopsies 
(fresh tumor biopsy specimens 
were required to confirm a 
complete response) 
Photograph/MRI: complete 
disappearance of target lesion 
Histology: negative ≥1 biopsies 
Photograph/MRI 
(unidimensional): partial 
response or stable disease 
allowed 
PR  Photograph (bidimensional): 
≥50% reduction in the sum of 
products of perpendicular 
diameters per WHO 
MRI (unidimensional): ≥30% 
reduction in the sum of 
diameters of all target lesions 
per RECIST v1.1 
Photograph/MRI 
(unidimensional): ≥30% 
reduction in the longest 
diameter of externally visible or 
radiographic dimension (if 
applicable, per RECIST v1.0) or 








increase in the sum of the 
longest diameter 
SD Neither sufficient shrinkage to 
qualify for PR nor sufficient 
increase to qualify for PD 
Neither sufficient shrinkage to 
qualify for PR nor sufficient 
increase to qualify for PD 
BCC,basal cell carcinoma; CR, complete response; laBCC, locally advanced basal cell carcinoma; 
mRECIST, modified RECIST; MRI, magnetic resonance imaging; PD, progressive disease; PR, partial 
response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease, WHO; World 
Health Organization.  
*mRECIST is a composite multimodal evaluation used to integrate MRI according to RECIST V1.1, 
standard and annotated color photography using WHO criteria, and histology in multiple biopsies based 
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Table 4 Composite overall response in laBCC determined by mRECIST and RECIST-like criteria. 
MRI* Photograph† Histology‡ 





PR (scar/fibrosis only) or 
SD (scar/fibrosis only) 
Negative 
Not available Negative 
NA 
CR Negative 
CR CR PR (scar/fibrosis only) or 





PR (scar/fibrosis only) or 
SD (scar/fibrosis only) 
Negative 
Not available Negative 
SD 
CR Negative 
PR CR PR (scar/fibrosis only) or 
SD (scar/fibrosis only) 
Negative 
CR 





















PR (scar/fibrosis only) 
NA 
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PR unknown 





PR PR PR 
PR (scar/fibrosis only) 
CR 
SD Positive or 
unknown 
SD PR 
SD (scar/fibrosis only) 
PR 
SD Positive or 
unknown 
SD PR 
SD (scar/fibrosis only) 
SD 
SD Any 












Unknown Any Unknown Unknown 
Unknown Any (except PD) Any Unknown Unknown 
PD Any Any PD PD 
Any PD Any PD PD 
BCC, basal cell carcinoma; CR, complete response; laBCC, locally advanced basal cell carcinoma; 
mRECIST, modified RECIST; MRI, magnetic resonance imaging; NA, not available; PD, progressive 
disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable 
disease.  
 
Adapted from "Long‐term efficacy and safety of sonidegib in patients with locally advanced and 
metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study" by JT 
Lear, et al. [CC BY-NC 4.0]. 
*Per RECIST v1.1. 
†Per World Health Organization criteria. 









§An independent review committee re-evaluated all assessments for the laBCC cohort to determine a 
composite response. 
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Table 5 Efficacy in patients with laBCC in the BOLT (18-month follow-up) and ERIVANCE (21-month 
follow-up) studies. 
Patients with laBCC 
Sonidegib 200 mg QD15 
Central review 
RECIST-like 




ORR n (%); 95% CI 40 (60.6); 47.8–72.4 30 (47.6); 35.5–60.6 
CR, n (%) 14 (21.2%) 14 (22.2%) 
PR, n (%) 26 (39.4%) 16 (25.4%) 
SD, n (%) 20 (30.3%) 22 (34.9%) 
PD, n (%) 1 (1.5%) 8 (12.7%) 
Unknown, n (%) 5 (7.6%) 3 (4.8%) 
BCC, basal cell carcinoma; CR, complete response; laBCC, locally advanced basal cell carcinoma; 
mRECIST, modified RECIST; ORR, objective response rate; PD, progressive disease; PR, partial 
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Table 6 Efficacy using mRECIST and RECIST criteria in patients with laBCC treated with sonidegib 200 
mg by central review at 18-month follow-up in the BOLT study. 
Patients with laBCC 







ORR n (%); 95% CI (56.1); 43.3–68.3 40 (60.6); 47.8–72.4 
CR, n (%) 3 (4.5%) 14 (21.2%) 
PR, n (%) 34 (51.5%) 26 (39.4%) 
SD, n (%) 23 (34.8%) 20 (30.3%) 
PD, n (%) 1 (1.5%) 1 (1.5%) 
Unkown, n (%) 5 (7.6%) 5 (7.6%) 
CR, complete response; laBCC, locally advanced basal cell carcinoma; mRECIST, modified RECIST; 
ORR, objective response rate; PD, progressive disease; PR, partial response; QD, once daily; RECIST, 
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Table 7 Duration of response and progression free survival in patients with laBCC treated with 
sonidegib 200 mg at 30 months and vismodegib 150 mg at 21 months by central review. 
Patients with laBCC 
Sonidegib 200 mg QD15 
Central review  
RECIST-like 
Vismodegib 150 mg QD26 











11/37 Not reported 





PFS, events 16 Not reported 






CI, confidence interbal; CR, complete response; DCR, disease control rate; DOR, duration of response; 
KM, Kaplan–Meier; laBCC, locally advanced basal cell carcinoma; ORR, objective response rate; PD, 
progressive disease; PFS, progression-free survival; PR, partial response; QD, once daily; RECIST, 
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Figure 1. Simulated unbound vismodegib concentration-time profiles after once daily dosing of 25 mg, 50 
mg, 75 mg, 100 mg, 150 mg, 270 mg, and 540 mg. Doses lower than 150 mg once daily lead to markedly 
lower unbound vismodegib concentrations. No further increase in vismodegib exposure 
occurs at doses higher than 150 mg. 
d, days. 
Adapted with copyright permission from LoRusso PM, et al. Pharmacokinetic dose-scheduling study of 
hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid 
tumors. Clin Cancer Res. 2011;17(17):5774–82. 
 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42
Total minimum follow-up (months)
BOLT (mRECIST/RECIST)11,15,25
ERIVANCE (RECIST)9,26,29
Central review + Investigator review Investigator review









































Figure 2. Analyses of the BOLT and ERIVANCE studies in patients with laBCC. 
*Median duration of follow-up (months). 













Figure 3. Photographs of locally advanced basal cell carcinoma lesion (laBCC) and lesion classification using 
BCC-RECIST-like and mRECIST protocol. a) LaBCC lesion at baseline; b) LaBCC after treatment with 
sonidegib 200 mg. Lesion response to treatment: MRI and photo assessment showed partial response; 
negative result on biopsy. Using mRECIST criteria, the composite overall response would be considered a 
partial response, whereas using BCC-RECIST-like criteria, this is considered a complete response (Table 2). 
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(95% Cl NE)
                   laBCC (n=37)
 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36
         Time since response (months)
Number of patients still at risk













Figure 4. Duration of response (DOR) in patients with locally advanced basal cell carcinoma lesion (laBCC) in 
the BOLT and ERIVANCE studies. a) Kaplan-Meier plot of DOR in patients with laBCC treated with sonidegib 
200 mg QD (n=37) by central review in the BOLT study;* B) Kaplan-Meier plot of DOR in patients with 
laBCC treated with vismodegib 150 mg QD (n=27) by central review in the ERIVANCE study.†CI, confidence 
interval; NE, not estimable. *Adapted from "Long‐term efficacy and safety of sonidegib in patients with 
locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT 
study" by JT Lear, et al. [CC BY-NC 4.0].†Adapted from European Medicines Agency. EMA/297688/2013 – 
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Figure 4. Duration of response (DOR) in patients with locally advanced basal cell carcinoma lesion (laBCC) in 
the BOLT and ERIVANCE studies. a) Kaplan-Meier plot of DOR in patients with laBCC treated with sonidegib 
200 mg QD (n=37) by central review in the BOLT study;* B) Kaplan-Meier plot of DOR in patients with 
laBCC treated with vismodegib 150 mg QD (n=27) by central review in the ERIVANCE study.†CI, confidence 
interval; NE, not estimable. *Adapted from "Long‐term efficacy and safety of sonidegib in patients with 
locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT 
study" by JT Lear, et al. [CC BY-NC 4.0].†Adapted from European Medicines Agency. EMA/297688/2013 – 
































) Kaplan-Meier median: 22.1 months
(95% Cl NE)
                   laBCC (n=66)
 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38
 Time since response (months)
Number of patients still at risk













Figure 5. Progression-free survival (PFS) in patients with locally advanced basal cell carcinoma lesion 
(laBCC) in the BOLT and ERIVANCE studies by central review: a) Kaplan-Meier plot of PFS in patients with 
laBCC treated with sonidegib 200 mg QD (n=66) by central review in the BOLT study;* b) Kaplan-Meier plot 
of PFS in patients with laBCC treated with vismodegib 150 mg QD (n=63) by central review in the ERIVNACE 
study.† CI, confidence interval; NE, not estimable; QD, once daily.*Adapted from "Long‐term efficacy and 
safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis 
of the randomized phase 2 BOLT study" by JT Lear, et al. [CC BY-NC 4.0].†Adapted from European 
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Figure 5. Progression-free survival (PFS) in patients with locally advanced basal cell carcinoma lesion 
(laBCC) in the BOLT and ERIVANCE studies by central review: a) Kaplan-Meier plot of PFS in patients with 
laBCC treated with sonidegib 200 mg QD (n=66) by central review in the BOLT study;* b) Kaplan-Meier plot 
of PFS in patients with laBCC treated with vismodegib 150 mg QD (n=63) by central review in the ERIVNACE 
study.† CI, confidence interval; NE, not estimable; QD, once daily.*Adapted from "Long‐term efficacy and 
safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis 
of the randomized phase 2 BOLT study" by JT Lear, et al. [CC BY-NC 4.0].†Adapted from European 
Medicines Agency. EMA/297688/2013 – Erivedge: EPAR - Public assessment report, April 2013. 
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Weight loss; 24 (30.4%)
Nausea; 31 (39.2%)
Elevated CK >2;12 (15.2%)
Diarrhea; 25 (31.6%)
Decreased appetite; 18 (22.8%)
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Figure 6. Time to onset and frequency of common adverse events (AEs) at 21 months in patients with locally 
advanced basal cell carcinoma lesion (laBCC) and metastatic basal cell carcinoma lesion (mBCC) in the BOLT 
and ERIVANCE studies. a) Graph of time to onset and frequency of common AEs in patients with laBCC and 
mBCC treated with sonidegib 200 mg QD (n=79).15,30 b) Graph of time to onset and frequency of common 
AEs in patients with laBCC and mBCC treated with vismodegib 150 mg QD (n=104).26,29AE, adverse 
events; CI, confidence interval; QD, once daily. 
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